FDA grants accelerated approval for subcutaneous amivantamab combination in selected head and neck cancers
Regulatory / securities filing · U.S. Food and Drug Administration
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and an anti-PD-(L)1 antibody. HPV-associated oropharyngeal cancer is excluded. In the 102-patient OrigAMI-4 efficacy population, response rate was 42%. Continued approval requires confirmatory clinical benefit; this is not traditional full approval.
Why it may matter
Analysis: The decision may expand demand for subcutaneous biologic formulation and delivery expertise, while indication restrictions and confirmatory requirements remain essential.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections